Article

Key clinical point: Sacituzumab govitecan outperformed chemotherapy in terms of overall survival outcomes and showed a manageable safety profile in patients with pretreated, endocrine-resistant hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (BC) who had limited treatment options.

Major finding: Sacituzumab govitecan vs chemotherapy improved overall survival by 3.2 months (hazard ratio 0.79; P  =  .020). No new adverse events (AE) were reported; however, 1 fatal AE (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.

Study details: Findings are from the phase 3 TROPiCS-02 study including 543 patients with pretreated, endocrine-resistant HR+/HER2− metastatic BC who were randomly assigned to receive either sacituzumab govitecan or single-agent chemotherapy of physician’s choice.

Disclosures: This study was funded by Gilead Sciences. Six authors declared being current or former employees of and owning stocks in Gilead Sciences, and several other authors declared ties with various sources, including Gilead Sciences.

Source: Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Aug 23). doi: 10.1016/S0140-6736(23)01245-X

Key clinical point: Sacituzumab govitecan outperformed chemotherapy in terms of overall survival outcomes and showed a manageable safety profile in patients with pretreated, endocrine-resistant hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (BC) who had limited treatment options.

Major finding: Sacituzumab govitecan vs chemotherapy improved overall survival by 3.2 months (hazard ratio 0.79; P  =  .020). No new adverse events (AE) were reported; however, 1 fatal AE (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.

Study details: Findings are from the phase 3 TROPiCS-02 study including 543 patients with pretreated, endocrine-resistant HR+/HER2− metastatic BC who were randomly assigned to receive either sacituzumab govitecan or single-agent chemotherapy of physician’s choice.

Disclosures: This study was funded by Gilead Sciences. Six authors declared being current or former employees of and owning stocks in Gilead Sciences, and several other authors declared ties with various sources, including Gilead Sciences.

Source: Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Aug 23). doi: 10.1016/S0140-6736(23)01245-X

Key clinical point: Sacituzumab govitecan outperformed chemotherapy in terms of overall survival outcomes and showed a manageable safety profile in patients with pretreated, endocrine-resistant hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (BC) who had limited treatment options.

Major finding: Sacituzumab govitecan vs chemotherapy improved overall survival by 3.2 months (hazard ratio 0.79; P  =  .020). No new adverse events (AE) were reported; however, 1 fatal AE (septic shock caused by neutropenic colitis) was determined to be related to sacituzumab govitecan treatment.

Study details: Findings are from the phase 3 TROPiCS-02 study including 543 patients with pretreated, endocrine-resistant HR+/HER2− metastatic BC who were randomly assigned to receive either sacituzumab govitecan or single-agent chemotherapy of physician’s choice.

Disclosures: This study was funded by Gilead Sciences. Six authors declared being current or former employees of and owning stocks in Gilead Sciences, and several other authors declared ties with various sources, including Gilead Sciences.

Source: Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Aug 23). doi: 10.1016/S0140-6736(23)01245-X

Key clinical point: This case-control study indicated that high dietary phosphorus intake (>1800 mg/day) almost doubled the risk for breast cancer (BC), thus warranting the evaluation of a low-phosphate diet in patients with BC.

Major finding: A high dietary phosphorus intake >1800 mg per day vs a low intake of 800-1000 mg per day was associated with an increased risk of developing BC (relative risk 2.30; P = .07).

Study details: This nested case-control study analyzed the data of 74 women with BC and 296 age-matched control individuals from the Study of Women’s Health Across the Nation, USA.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Brown RB et al. High dietary phosphorus is associated with increased breast cancer risk in a U.S. cohort of middle-age women. Nutrients. 2023;15(17):3735 (Aug 25). doi: 10.3390/nu15173735

Key clinical point: This case-control study indicated that high dietary phosphorus intake (>1800 mg/day) almost doubled the risk for breast cancer (BC), thus warranting the evaluation of a low-phosphate diet in patients with BC.

Major finding: A high dietary phosphorus intake >1800 mg per day vs a low intake of 800-1000 mg per day was associated with an increased risk of developing BC (relative risk 2.30; P = .07).

Study details: This nested case-control study analyzed the data of 74 women with BC and 296 age-matched control individuals from the Study of Women’s Health Across the Nation, USA.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Brown RB et al. High dietary phosphorus is associated with increased breast cancer risk in a U.S. cohort of middle-age women. Nutrients. 2023;15(17):3735 (Aug 25). doi: 10.3390/nu15173735

Key clinical point: This case-control study indicated that high dietary phosphorus intake (>1800 mg/day) almost doubled the risk for breast cancer (BC), thus warranting the evaluation of a low-phosphate diet in patients with BC.

Major finding: A high dietary phosphorus intake >1800 mg per day vs a low intake of 800-1000 mg per day was associated with an increased risk of developing BC (relative risk 2.30; P = .07).

Study details: This nested case-control study analyzed the data of 74 women with BC and 296 age-matched control individuals from the Study of Women’s Health Across the Nation, USA.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Brown RB et al. High dietary phosphorus is associated with increased breast cancer risk in a U.S. cohort of middle-age women. Nutrients. 2023;15(17):3735 (Aug 25). doi: 10.3390/nu15173735

Key clinical point: The post-diagnostic use of statins and metformin substantially reduced the risk for breast cancer (BC)-specific deaths in patients age ≥ 50 years with primary invasive BC.

Major finding: At a median follow-up of 6.1 years, 2169 BC-specific deaths were reported. Patients who did vs did not use statins (hazard ratio [HR] 0.84; 95% CI 0.75-0.94) and those who used metformin vs other non-metformin antidiabetics (HR 0.70; 95% CI 0.51-0.96) showed 16% and 30% improvement in BC-specific survival rates, respectively.

Study details: Findings are from a nationwide population-based cohort study including 26,190 women with BC, of whom 20%, 29%, and 6% were post-diagnostic users of low-dose aspirin, statins, and metformin, respectively.

Disclosures: This study was funded by the Research Council of Norway. The authors declared no conflicts of interest.

Source: Löfling LL et al. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: A Norwegian population-based cohort study. Breast Cancer Res. 2023;25:101 (Aug 30). doi: 10.1186/s13058-023-01697-2

Key clinical point: The post-diagnostic use of statins and metformin substantially reduced the risk for breast cancer (BC)-specific deaths in patients age ≥ 50 years with primary invasive BC.

Major finding: At a median follow-up of 6.1 years, 2169 BC-specific deaths were reported. Patients who did vs did not use statins (hazard ratio [HR] 0.84; 95% CI 0.75-0.94) and those who used metformin vs other non-metformin antidiabetics (HR 0.70; 95% CI 0.51-0.96) showed 16% and 30% improvement in BC-specific survival rates, respectively.

Study details: Findings are from a nationwide population-based cohort study including 26,190 women with BC, of whom 20%, 29%, and 6% were post-diagnostic users of low-dose aspirin, statins, and metformin, respectively.

Disclosures: This study was funded by the Research Council of Norway. The authors declared no conflicts of interest.

Source: Löfling LL et al. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: A Norwegian population-based cohort study. Breast Cancer Res. 2023;25:101 (Aug 30). doi: 10.1186/s13058-023-01697-2

Key clinical point: The post-diagnostic use of statins and metformin substantially reduced the risk for breast cancer (BC)-specific deaths in patients age ≥ 50 years with primary invasive BC.

Major finding: At a median follow-up of 6.1 years, 2169 BC-specific deaths were reported. Patients who did vs did not use statins (hazard ratio [HR] 0.84; 95% CI 0.75-0.94) and those who used metformin vs other non-metformin antidiabetics (HR 0.70; 95% CI 0.51-0.96) showed 16% and 30% improvement in BC-specific survival rates, respectively.

Study details: Findings are from a nationwide population-based cohort study including 26,190 women with BC, of whom 20%, 29%, and 6% were post-diagnostic users of low-dose aspirin, statins, and metformin, respectively.

Disclosures: This study was funded by the Research Council of Norway. The authors declared no conflicts of interest.

Source: Löfling LL et al. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: A Norwegian population-based cohort study. Breast Cancer Res. 2023;25:101 (Aug 30). doi: 10.1186/s13058-023-01697-2

Key clinical point: Patients with breast cancer (BC), particularly those with left-sided BC who underwent radiotherapy, faced the risk of developing major ischemic events.

Major finding: At a median follow-up of 7.9 years, the incidence of a major ischemic event was reported in 4.1% of patients, with the incidence rate being significantly higher in patients with left-sided vs right-sided BC (P = .044). The risk for major ischemic events increased by 6.2% per Gy increase in the mean heart dose (hazard ratio 1.062; P = .012).

Study details: This retrospective study included 2158 women with BC who received adjuvant radiotherapy.

Disclosures: This study was supported by the Taipei Veterans General Hospital, Taiwan, and other sources. The authors declared no conflicts of interest.

Source: Lai TY et al. Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy. Eur Heart J. 2023 (Aug 16). doi: 10.1093/eurheartj/ehad462

Key clinical point: Patients with breast cancer (BC), particularly those with left-sided BC who underwent radiotherapy, faced the risk of developing major ischemic events.

Major finding: At a median follow-up of 7.9 years, the incidence of a major ischemic event was reported in 4.1% of patients, with the incidence rate being significantly higher in patients with left-sided vs right-sided BC (P = .044). The risk for major ischemic events increased by 6.2% per Gy increase in the mean heart dose (hazard ratio 1.062; P = .012).

Study details: This retrospective study included 2158 women with BC who received adjuvant radiotherapy.

Disclosures: This study was supported by the Taipei Veterans General Hospital, Taiwan, and other sources. The authors declared no conflicts of interest.

Source: Lai TY et al. Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy. Eur Heart J. 2023 (Aug 16). doi: 10.1093/eurheartj/ehad462

Key clinical point: Patients with breast cancer (BC), particularly those with left-sided BC who underwent radiotherapy, faced the risk of developing major ischemic events.

Major finding: At a median follow-up of 7.9 years, the incidence of a major ischemic event was reported in 4.1% of patients, with the incidence rate being significantly higher in patients with left-sided vs right-sided BC (P = .044). The risk for major ischemic events increased by 6.2% per Gy increase in the mean heart dose (hazard ratio 1.062; P = .012).

Study details: This retrospective study included 2158 women with BC who received adjuvant radiotherapy.

Disclosures: This study was supported by the Taipei Veterans General Hospital, Taiwan, and other sources. The authors declared no conflicts of interest.

Source: Lai TY et al. Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy. Eur Heart J. 2023 (Aug 16). doi: 10.1093/eurheartj/ehad462

Key clinical point: Adjuvant endocrine therapy (ET) significantly reduces the incidence of distant metastasis in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) T1a/bN0M0 breast cancer (BC).

Major finding: The 9-year cumulative incidence of distant metastasis was significantly lower in patients who did vs did not receive adjuvant ET (1.5% vs 2.6%; adjusted subdistribution hazard ratio 0.54; P = .027), with the risk factors for distant metastasis being mastectomy (P = .022), no prior receipt of ET (P = .027), lymphatic invasion (P = .004), and higher nuclear grade (P = .047).

Study details: Findings are from a multicenter cohort study including 4758 patients with ER+ /HER2− T1a/bN0M0 BC who underwent surgery, of whom 3991 patients were administered adjuvant ET.

Disclosures: This study was partly supported by the National Cancer Center Research and Development Fund and the Practical Research for Innovative Cancer Control, Japan. The authors declared no conflicts of interest.

Source: Sasada S et al. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast Cancer Res Treat. 2023 (Sep 9). doi: 10.1007/s10549-023-07097-6

Key clinical point: Adjuvant endocrine therapy (ET) significantly reduces the incidence of distant metastasis in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) T1a/bN0M0 breast cancer (BC).

Major finding: The 9-year cumulative incidence of distant metastasis was significantly lower in patients who did vs did not receive adjuvant ET (1.5% vs 2.6%; adjusted subdistribution hazard ratio 0.54; P = .027), with the risk factors for distant metastasis being mastectomy (P = .022), no prior receipt of ET (P = .027), lymphatic invasion (P = .004), and higher nuclear grade (P = .047).

Study details: Findings are from a multicenter cohort study including 4758 patients with ER+ /HER2− T1a/bN0M0 BC who underwent surgery, of whom 3991 patients were administered adjuvant ET.

Disclosures: This study was partly supported by the National Cancer Center Research and Development Fund and the Practical Research for Innovative Cancer Control, Japan. The authors declared no conflicts of interest.

Source: Sasada S et al. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast Cancer Res Treat. 2023 (Sep 9). doi: 10.1007/s10549-023-07097-6

Key clinical point: Adjuvant endocrine therapy (ET) significantly reduces the incidence of distant metastasis in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) T1a/bN0M0 breast cancer (BC).

Major finding: The 9-year cumulative incidence of distant metastasis was significantly lower in patients who did vs did not receive adjuvant ET (1.5% vs 2.6%; adjusted subdistribution hazard ratio 0.54; P = .027), with the risk factors for distant metastasis being mastectomy (P = .022), no prior receipt of ET (P = .027), lymphatic invasion (P = .004), and higher nuclear grade (P = .047).

Study details: Findings are from a multicenter cohort study including 4758 patients with ER+ /HER2− T1a/bN0M0 BC who underwent surgery, of whom 3991 patients were administered adjuvant ET.

Disclosures: This study was partly supported by the National Cancer Center Research and Development Fund and the Practical Research for Innovative Cancer Control, Japan. The authors declared no conflicts of interest.

Source: Sasada S et al. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast Cancer Res Treat. 2023 (Sep 9). doi: 10.1007/s10549-023-07097-6

Key clinical point: Neoadjuvant high-dose alkylating chemotherapy did not improve the Neoadjuvant Response Index (NRI) scores in patients with BRCA1- or BRCA2-pathway-altered (BRCA-altered) triple-negative breast cancer (TNBC).

Major finding: The NRI scores were comparable between the conventional and high-dose chemotherapy treatment groups (0.72 vs 0.78; P = .41). Adverse events, such as fatigue, infections, nausea, oral mucositis, and diarrhea, were more prevalent in the high-dose vs conventional chemotherapy group, although no treatment-related deaths occurred in either group.

Study details: Findings are from the phase 3 neo-TN study that included 122 patients with BRCA-altered TNBC who were randomly assigned to receive either conventional or high-dose chemotherapy.

Disclosures: This study was supported by The Dutch Cancer Foundation and the Schumacher Kramer Foundation, Amsterdam. The authors declared no conflicts of interest.

Source: Vliek S et al. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: The randomized phase III NeoTN trial. NPJ Breast Cancer. 2023;9:75 (Sep 9). doi: 10.1038/s41523-023-00580-9

Key clinical point: Neoadjuvant high-dose alkylating chemotherapy did not improve the Neoadjuvant Response Index (NRI) scores in patients with BRCA1- or BRCA2-pathway-altered (BRCA-altered) triple-negative breast cancer (TNBC).

Major finding: The NRI scores were comparable between the conventional and high-dose chemotherapy treatment groups (0.72 vs 0.78; P = .41). Adverse events, such as fatigue, infections, nausea, oral mucositis, and diarrhea, were more prevalent in the high-dose vs conventional chemotherapy group, although no treatment-related deaths occurred in either group.

Study details: Findings are from the phase 3 neo-TN study that included 122 patients with BRCA-altered TNBC who were randomly assigned to receive either conventional or high-dose chemotherapy.

Disclosures: This study was supported by The Dutch Cancer Foundation and the Schumacher Kramer Foundation, Amsterdam. The authors declared no conflicts of interest.

Source: Vliek S et al. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: The randomized phase III NeoTN trial. NPJ Breast Cancer. 2023;9:75 (Sep 9). doi: 10.1038/s41523-023-00580-9

Key clinical point: Neoadjuvant high-dose alkylating chemotherapy did not improve the Neoadjuvant Response Index (NRI) scores in patients with BRCA1- or BRCA2-pathway-altered (BRCA-altered) triple-negative breast cancer (TNBC).

Major finding: The NRI scores were comparable between the conventional and high-dose chemotherapy treatment groups (0.72 vs 0.78; P = .41). Adverse events, such as fatigue, infections, nausea, oral mucositis, and diarrhea, were more prevalent in the high-dose vs conventional chemotherapy group, although no treatment-related deaths occurred in either group.

Study details: Findings are from the phase 3 neo-TN study that included 122 patients with BRCA-altered TNBC who were randomly assigned to receive either conventional or high-dose chemotherapy.

Disclosures: This study was supported by The Dutch Cancer Foundation and the Schumacher Kramer Foundation, Amsterdam. The authors declared no conflicts of interest.

Source: Vliek S et al. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: The randomized phase III NeoTN trial. NPJ Breast Cancer. 2023;9:75 (Sep 9). doi: 10.1038/s41523-023-00580-9

Key clinical point: In women with high levels of background parenchymal enhancement (BPE), a simultaneous high-temporal/high-spatial resolution (HTHS) magnetic resonance imaging (MRI) protocol detected an additional 15.7 cases of breast cancer (BC) per 1000 patients than the standard high-spatial resolution MRI protocol while concomitantly decreasing the rate of unnecessary biopsies by ~10%.

Major finding: HTHS vs standard protocol improved the BC detection rate per 1000 patients (23.6 vs 7.9; P = .021), increased the positive predictive value of biopsy (16.0% vs 6.3%; P = .014), and decreased the rate of unnecessary biopsies by 9.8%.

Study details: This retrospective study included 1414 women with 1481 high-BPE examinations.

Disclosures: This study was supported partly by the US National Cancer Institute. JS Sung, K Feigin, and K Pinker declared serving in leadership roles and consulting roles or as members of speakers’ bureaus of or receiving research funding from various sources.

Source: Eskreis-Winkler S et al. High-temporal/high-spatial resolution breast magnetic resonance imaging improves diagnostic accuracy compared with standard breast magnetic resonance imaging in patients with high background parenchymal enhancement. J Clin Oncol. 2023 (Aug 10). doi: 10.1200/JCO.22.00635

Key clinical point: In women with high levels of background parenchymal enhancement (BPE), a simultaneous high-temporal/high-spatial resolution (HTHS) magnetic resonance imaging (MRI) protocol detected an additional 15.7 cases of breast cancer (BC) per 1000 patients than the standard high-spatial resolution MRI protocol while concomitantly decreasing the rate of unnecessary biopsies by ~10%.

Major finding: HTHS vs standard protocol improved the BC detection rate per 1000 patients (23.6 vs 7.9; P = .021), increased the positive predictive value of biopsy (16.0% vs 6.3%; P = .014), and decreased the rate of unnecessary biopsies by 9.8%.

Study details: This retrospective study included 1414 women with 1481 high-BPE examinations.

Disclosures: This study was supported partly by the US National Cancer Institute. JS Sung, K Feigin, and K Pinker declared serving in leadership roles and consulting roles or as members of speakers’ bureaus of or receiving research funding from various sources.

Source: Eskreis-Winkler S et al. High-temporal/high-spatial resolution breast magnetic resonance imaging improves diagnostic accuracy compared with standard breast magnetic resonance imaging in patients with high background parenchymal enhancement. J Clin Oncol. 2023 (Aug 10). doi: 10.1200/JCO.22.00635

Key clinical point: In women with high levels of background parenchymal enhancement (BPE), a simultaneous high-temporal/high-spatial resolution (HTHS) magnetic resonance imaging (MRI) protocol detected an additional 15.7 cases of breast cancer (BC) per 1000 patients than the standard high-spatial resolution MRI protocol while concomitantly decreasing the rate of unnecessary biopsies by ~10%.

Major finding: HTHS vs standard protocol improved the BC detection rate per 1000 patients (23.6 vs 7.9; P = .021), increased the positive predictive value of biopsy (16.0% vs 6.3%; P = .014), and decreased the rate of unnecessary biopsies by 9.8%.

Study details: This retrospective study included 1414 women with 1481 high-BPE examinations.

Disclosures: This study was supported partly by the US National Cancer Institute. JS Sung, K Feigin, and K Pinker declared serving in leadership roles and consulting roles or as members of speakers’ bureaus of or receiving research funding from various sources.

Source: Eskreis-Winkler S et al. High-temporal/high-spatial resolution breast magnetic resonance imaging improves diagnostic accuracy compared with standard breast magnetic resonance imaging in patients with high background parenchymal enhancement. J Clin Oncol. 2023 (Aug 10). doi: 10.1200/JCO.22.00635

Key clinical point: In patients with locally advanced triple-negative breast cancer (TNBC), neoadjuvant apatinib (Apa) plus dose-dense paclitaxel and carboplatin (ddTCb) was more effective in improving clinical outcomes than ddTCb alone and showed an acceptable safety profile.

Major finding: A significantly higher proportion of patients in the Apa + ddTCb vs ddTCb treatment group achieved pathological complete response (60.9% vs 30.4%; P = .009) and underwent breast-conserving surgery (47.8% vs 21.7%; P = .016). The incidence of adverse events was higher in the Apa + ddTCb treatment arm, but they were generally acceptable.

Study details: This prospective cohort study included 23 patients with stages I-IIIC TNBC who received neoadjuvant Apa + ddTCb therapy matched with 69 patients with stages I-IIIC TNBC who received neoadjuvant ddTCb therapy only.

Disclosures: This study was supported by CAMS Innovation Fund for Medical Sciences and the Translational research project of Medical Oncology Key Foundation of Cancer Hospital, Chinese Academy of Medical Sciences. The authors declared no conflicts of interest.

Source: Liu J, Xu B, Zhang P, et al. Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. Int J Cancer. 2023 (Sep 7). doi: 10.1002/ijc.34717

Key clinical point: In patients with locally advanced triple-negative breast cancer (TNBC), neoadjuvant apatinib (Apa) plus dose-dense paclitaxel and carboplatin (ddTCb) was more effective in improving clinical outcomes than ddTCb alone and showed an acceptable safety profile.

Major finding: A significantly higher proportion of patients in the Apa + ddTCb vs ddTCb treatment group achieved pathological complete response (60.9% vs 30.4%; P = .009) and underwent breast-conserving surgery (47.8% vs 21.7%; P = .016). The incidence of adverse events was higher in the Apa + ddTCb treatment arm, but they were generally acceptable.

Study details: This prospective cohort study included 23 patients with stages I-IIIC TNBC who received neoadjuvant Apa + ddTCb therapy matched with 69 patients with stages I-IIIC TNBC who received neoadjuvant ddTCb therapy only.

Disclosures: This study was supported by CAMS Innovation Fund for Medical Sciences and the Translational research project of Medical Oncology Key Foundation of Cancer Hospital, Chinese Academy of Medical Sciences. The authors declared no conflicts of interest.

Source: Liu J, Xu B, Zhang P, et al. Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. Int J Cancer. 2023 (Sep 7). doi: 10.1002/ijc.34717

Key clinical point: In patients with locally advanced triple-negative breast cancer (TNBC), neoadjuvant apatinib (Apa) plus dose-dense paclitaxel and carboplatin (ddTCb) was more effective in improving clinical outcomes than ddTCb alone and showed an acceptable safety profile.

Major finding: A significantly higher proportion of patients in the Apa + ddTCb vs ddTCb treatment group achieved pathological complete response (60.9% vs 30.4%; P = .009) and underwent breast-conserving surgery (47.8% vs 21.7%; P = .016). The incidence of adverse events was higher in the Apa + ddTCb treatment arm, but they were generally acceptable.

Study details: This prospective cohort study included 23 patients with stages I-IIIC TNBC who received neoadjuvant Apa + ddTCb therapy matched with 69 patients with stages I-IIIC TNBC who received neoadjuvant ddTCb therapy only.

Disclosures: This study was supported by CAMS Innovation Fund for Medical Sciences and the Translational research project of Medical Oncology Key Foundation of Cancer Hospital, Chinese Academy of Medical Sciences. The authors declared no conflicts of interest.

Source: Liu J, Xu B, Zhang P, et al. Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. Int J Cancer. 2023 (Sep 7). doi: 10.1002/ijc.34717

Key clinical point: Trifluridine/tipiracil (FTD/TPI) showed promising anti-tumor activity with a manageable safety profile regardless of prior exposure to fluoropyrimidine therapy in patients with metastatic breast cancer (BC).

Major finding: The median durations of progression-free survival were 5.7 months and 9.4 months in patients with and without prior exposure to fluoropyrimidine therapy, respectively. Neutropenia (81.8%), fatigue (29.7%), anorexia (25.7%), and nausea (25.7%) were the most common all-grade treatment-related adverse events.

Study details: Findings are from a phase 2 study including 74 patients with metastatic BC with or without prior exposure to fluoropyrimidine therapy who received FTD/TPI.

Disclosures: This study was funded by a grant from the National Medical Research Council, Singapore. Some authors declared receiving research funding, honoraria, consulting fees, or travel support from or having other ties with various sources.

Source: Lim JSJ et al. Phase II study of trifluridine/tipiracil (FTD/TPI) in metastatic breast cancers with or without prior exposure to fluoropyrimidines. Eur J Cancer. 2023;113311 (Aug 25). doi: 10.1016/j.ejca.2023.113311

Key clinical point: Trifluridine/tipiracil (FTD/TPI) showed promising anti-tumor activity with a manageable safety profile regardless of prior exposure to fluoropyrimidine therapy in patients with metastatic breast cancer (BC).

Major finding: The median durations of progression-free survival were 5.7 months and 9.4 months in patients with and without prior exposure to fluoropyrimidine therapy, respectively. Neutropenia (81.8%), fatigue (29.7%), anorexia (25.7%), and nausea (25.7%) were the most common all-grade treatment-related adverse events.

Study details: Findings are from a phase 2 study including 74 patients with metastatic BC with or without prior exposure to fluoropyrimidine therapy who received FTD/TPI.

Disclosures: This study was funded by a grant from the National Medical Research Council, Singapore. Some authors declared receiving research funding, honoraria, consulting fees, or travel support from or having other ties with various sources.

Source: Lim JSJ et al. Phase II study of trifluridine/tipiracil (FTD/TPI) in metastatic breast cancers with or without prior exposure to fluoropyrimidines. Eur J Cancer. 2023;113311 (Aug 25). doi: 10.1016/j.ejca.2023.113311

Key clinical point: Trifluridine/tipiracil (FTD/TPI) showed promising anti-tumor activity with a manageable safety profile regardless of prior exposure to fluoropyrimidine therapy in patients with metastatic breast cancer (BC).

Major finding: The median durations of progression-free survival were 5.7 months and 9.4 months in patients with and without prior exposure to fluoropyrimidine therapy, respectively. Neutropenia (81.8%), fatigue (29.7%), anorexia (25.7%), and nausea (25.7%) were the most common all-grade treatment-related adverse events.

Study details: Findings are from a phase 2 study including 74 patients with metastatic BC with or without prior exposure to fluoropyrimidine therapy who received FTD/TPI.

Disclosures: This study was funded by a grant from the National Medical Research Council, Singapore. Some authors declared receiving research funding, honoraria, consulting fees, or travel support from or having other ties with various sources.

Source: Lim JSJ et al. Phase II study of trifluridine/tipiracil (FTD/TPI) in metastatic breast cancers with or without prior exposure to fluoropyrimidines. Eur J Cancer. 2023;113311 (Aug 25). doi: 10.1016/j.ejca.2023.113311

Key clinical point: Giredestrant demonstrated stronger anti-proliferative activity than anastrozole and was well-tolerated in patients with estrogen receptor-positive (ER+ ), human epidermal growth factor receptor 2-negative (HER2−), untreated early breast cancer (BC).

Major finding: At week 2, giredestrant vs anastrozole had a stronger anti-proliferative effect as indicated by greater relative geometric mean reduction of Ki67 scores (−75% vs −67%; P = .043). Neutropenia (26% and 27%, respectively) and decreased neutrophil count (15% and 15%, respectively) were the most common grade 3-4 adverse events observed in the giredestrant + palbociclib and anastrozole + palbociclib treatment arms.

Study details: Findings are from the phase 2 coopERA Breast Cancer trial including 221 postmenopausal patients with clinical T stage (cT)1c to cT4a-c, ER+ /HER2− early BC who were randomly assigned to receive giredestrant or anastrozole in combination with palbociclib.

Disclosures: This study was funded by F Hoffmann-La Roche. Seven authors declared being employees or stockholders of F Hoffmann-La Roche, and the other authors declared ties with various sources.

Source: Hurvitz SA et al on behalf of thecoopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): An open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24(9):1029-1041 (Aug 29). doi: 10.1016/S1470-2045(23)00268-1

Key clinical point: Giredestrant demonstrated stronger anti-proliferative activity than anastrozole and was well-tolerated in patients with estrogen receptor-positive (ER+ ), human epidermal growth factor receptor 2-negative (HER2−), untreated early breast cancer (BC).

Major finding: At week 2, giredestrant vs anastrozole had a stronger anti-proliferative effect as indicated by greater relative geometric mean reduction of Ki67 scores (−75% vs −67%; P = .043). Neutropenia (26% and 27%, respectively) and decreased neutrophil count (15% and 15%, respectively) were the most common grade 3-4 adverse events observed in the giredestrant + palbociclib and anastrozole + palbociclib treatment arms.

Study details: Findings are from the phase 2 coopERA Breast Cancer trial including 221 postmenopausal patients with clinical T stage (cT)1c to cT4a-c, ER+ /HER2− early BC who were randomly assigned to receive giredestrant or anastrozole in combination with palbociclib.

Disclosures: This study was funded by F Hoffmann-La Roche. Seven authors declared being employees or stockholders of F Hoffmann-La Roche, and the other authors declared ties with various sources.

Source: Hurvitz SA et al on behalf of thecoopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): An open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24(9):1029-1041 (Aug 29). doi: 10.1016/S1470-2045(23)00268-1

Key clinical point: Giredestrant demonstrated stronger anti-proliferative activity than anastrozole and was well-tolerated in patients with estrogen receptor-positive (ER+ ), human epidermal growth factor receptor 2-negative (HER2−), untreated early breast cancer (BC).

Major finding: At week 2, giredestrant vs anastrozole had a stronger anti-proliferative effect as indicated by greater relative geometric mean reduction of Ki67 scores (−75% vs −67%; P = .043). Neutropenia (26% and 27%, respectively) and decreased neutrophil count (15% and 15%, respectively) were the most common grade 3-4 adverse events observed in the giredestrant + palbociclib and anastrozole + palbociclib treatment arms.

Study details: Findings are from the phase 2 coopERA Breast Cancer trial including 221 postmenopausal patients with clinical T stage (cT)1c to cT4a-c, ER+ /HER2− early BC who were randomly assigned to receive giredestrant or anastrozole in combination with palbociclib.

Disclosures: This study was funded by F Hoffmann-La Roche. Seven authors declared being employees or stockholders of F Hoffmann-La Roche, and the other authors declared ties with various sources.

Source: Hurvitz SA et al on behalf of thecoopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): An open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24(9):1029-1041 (Aug 29). doi: 10.1016/S1470-2045(23)00268-1